Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue.
The trailing-twelve-month revenue at Neogen NEOG is $179.10 million. Neogen had $61.33 million in total cash for the latest quarter.
The trailing-twelve-month revenue at Meridian Bioscience VIVO is $169.11 million. Meridian Bioscience's PEG ratio is 1.37.
The trailing-twelve-month revenue at Abaxis ABAX is $156.60 million. Abaxis's ROE for the same period is 7.97%.
The trailing-twelve-month revenue at Quidel QDEL is $136.97 million. Quidel had $21.56 million in total cash for the latest quarter.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in